Construction of a Rat Model of Hemilateral Parkinson&rsquo;s Disease Induced by Human Wild-Type &alpha;-Synuclein Overexpression

Qi Pan,1,&ast; Jianyue Lu,2,&ast; Zongyu Xiao,3 Huaming Zhang,4 Guanghao Liu,4 Yiying Li5,&ast; 1Department of Neurosurgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, People’s Republic of China; 2International School, Sehan University, Youngam-...

Full description

Bibliographic Details
Published in:	Neuropsychiatric Disease and Treatment
Main Authors:	Pan Q, Lu J, Xiao Z, Zhang H, Liu G, Li Y
Format:	Article
Language:	English
Published:	Dove Medical Press 2025-09-01
Subjects:	α-Synuclein dopaminergic neurons Parkinson's disease pathogenesis substantia nigra
Online Access:	https://www.dovepress.com/construction-of-a-rat-model-of-hemilateral-parkinsons-disease-induced--peer-reviewed-fulltext-article-NDT

Similar Items

Opposing effects of β-2 and β-1 adrenergic receptor signaling on neuroinflammation and dopaminergic neuron survival in α-synuclein-mediated neurotoxicity
by: Daniel Torrente, et al.
Published: (2023-03-01)

The interaction of tPA with NMDAR1 drives neuroinflammation and neurodegeneration in α-synuclein-mediated neurotoxicity
by: Daniel Torrente, et al.
Published: (2025-01-01)

Abnormal alpha-synuclein reduces nigral voltage-dependent anion channel 1 in sporadic and experimental Parkinson's disease
by: Yaping Chu, et al.
Published: (2014-09-01)

α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease
by: Fanni F. Geibl, et al.
Published: (2024-10-01)

Protein Expression of TXNIP in the Dopaminergic Neurons of Subjects with Parkinson’s Disease: Evidence from a Pilot Study
by: Francesca A. Schillaci, et al.
Published: (2025-08-01)

α-Synuclein expression in the substantia nigra of MPTP-lesioned non-human primates
by: Maya G. Purisai, et al.
Published: (2005-12-01)

The Nigral Coup in Parkinson’s Disease by α-Synuclein and Its Associated Rebels
by: Jeswinder Sian-Hulsmann, et al.
Published: (2021-03-01)

Can Interactions Between α-Synuclein, Dopamine and Calcium Explain Selective Neurodegeneration in Parkinson's Disease?
by: Michael R. Post, et al.
Published: (2018-03-01)

Calcium, Bioenergetics, and Parkinson’s Disease
by: Enrico Zampese, et al.
Published: (2020-09-01)

Pretreatment with Human Lactoferrin Had a Positive Effect on the Dynamics of Mouse Nigrostriatal System Recovery after Acute MPTP Exposure
by: Marina Yu. Kopaeva, et al.
Published: (2021-01-01)

Tau gene transfer, but not alpha-synuclein, induces both progressive dopamine neuron degeneration and rotational behavior in the rat
by: Ronald L. Klein, et al.
Published: (2005-10-01)

Unraveling the mystery: How autophagy deficiency in dopaminergic neurons drives human Parkinson’s disease
by: Sachiko Noda, et al.
Published: (2025-07-01)

Genetic inactivation of alpha-synuclein affects embryonic development of dopaminergic neurons of the substantia nigra, but not the ventral tegmental area, in mouse brain
by: Tatiana V. Tarasova, et al.
Published: (2018-05-01)

Cell Therapy for Parkinson’s Disease
by: Surabhi Shastry, et al.
Published: (2023-11-01)

The Neuro-Protective Effects of the TSPO Ligands CB86 and CB204 on 6-OHDA-Induced PC12 Cell Death as an In Vitro Model for Parkinson’s Disease
by: Sheelu Monga, et al.
Published: (2021-11-01)

Stable isotope labeling and ultra-high-resolution NanoSIMS imaging reveal alpha-synuclein-induced changes in neuronal metabolism in vivo
by: Sofia Spataro, et al.
Published: (2023-09-01)

Modelling Non-motor Symptoms of Parkinson’s Disease: AAV Mediated Overexpression of Alpha-synuclein in Rat Hippocampus and Basal Ganglia
by: Sevgi Uğur Mutluay, et al.
Published: (2020-12-01)

Editorial: Biomarkers and Pathogenesis of Alpha-Synuclein in Parkinson's Disease
by: Puyu Li, et al.
Published: (2021-10-01)

Neuroprotective effects of osmotin in Parkinson’s disease-associated pathology via the AdipoR1/MAPK/AMPK/mTOR signaling pathways
by: Jun Sung Park, et al.
Published: (2023-08-01)

Altered Development of Mesencephalic Dopaminergic Neurons in SIDS: New Insights into Understanding Sudden Infant Death Pathogenesis
by: Anna Maria Lavezzi
Published: (2021-10-01)

Primary cilia in Parkinson’s disease: summative roles in signaling pathways, genes, defective mitochondrial function, and substantia nigra dopaminergic neurons
by: Zijiao Tian, et al.
Published: (2024-09-01)

Neuron-Astrocyte Interactions in Parkinson’s Disease
by: Ikuko Miyazaki, et al.
Published: (2020-12-01)

Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons from Familial Parkinson’s Disease Patients Display α-Synuclein Pathology and Abnormal Mitochondrial Morphology
by: Xiaojun Diao, et al.
Published: (2021-09-01)

Reduction of alpha-synuclein oligomers in preclinical models of Parkinson’s disease by electrical stimulation in vitro and deep brain stimulation in vivo
by: Eun Jung Lee, et al.
Published: (2024-03-01)

Transcriptional dysregulation in a transgenic model of Parkinson disease
by: Talene A. Yacoubian, et al.
Published: (2008-03-01)

Alpha‐synuclein dynamics in induced pluripotent stem cell‐derived dopaminergic neurons from a Parkinson’s disease patient (PARK4) with SNCA triplication
by: Hayato Fukusumi, et al.
Published: (2021-02-01)

The role of NURR1 in metabolic abnormalities of Parkinson’s disease
by: Murad Al-Nusaif, et al.
Published: (2022-06-01)

Synuclein Proteins in MPTP-Induced Death of Substantia Nigra Pars Compacta Dopaminergic Neurons
by: Valeria V. Goloborshcheva, et al.
Published: (2022-09-01)

Amelioration of Motor Performance and Nigrostriatal Dopamine Cell Volume Using a Novel Far-Infrared Ceramic Blanket in an A53T Alpha-Synuclein Transgenic Parkinson’s Disease Mouse Model
by: Frederick Robert Carrick, et al.
Published: (2023-12-01)

The raphe nuclei are the early lesion site of gastric α-synuclein propagation to the substantia nigra
by: Chenglu Zhang, et al.
Published: (2024-05-01)

Transcranial sonography in Parkinson’s disease
by: I. V. Bayborodina, et al.
Published: (2018-03-01)

FGF, Mechanism of Action, Role in Parkinson’s Disease, and Therapeutics
by: Yiqiu Liu, et al.
Published: (2021-06-01)

Height and nigral neuron density in Parkinson’s disease
by: Laura Saari, et al.
Published: (2022-07-01)

Activation and polarization of striatal microglia and astrocytes are involved in bradykinesia and allodynia in early-stage parkinsonian mice
by: Xue Zhang, et al.
Published: (2024-07-01)

Unraveling Parkinson’s disease: from dopaminergic dysfunction to novel therapeutic targets
by: Kuntal Godde, et al.
Published: (2025-09-01)

Expression of Genes Encoding Receptors for Classical Neurotransmitters, Neuropeptides and Hormones in the Substantia Nigra, Especially in Dopaminergic Neurons, in Intact Mice and Mouse Models of Parkinson’s Disease
by: Dmitry Troshev, et al.
Published: (2025-10-01)

Analysis of α-syn and parkin interaction in mediating neuronal death in Drosophila model of Parkinson's disease
by: Sonia Narwal, et al.
Published: (2024-01-01)

Is alpha-synuclein loss-of-function a contributor to parkinsonian pathology? Evidence from non-human primates
by: Timothy J Collier, et al.
Published: (2016-01-01)

Toll-like Receptor 4 Is Upregulated in Parkinson’s Disease Patients and Co-Localizes with pSer129αSyn: A Possible Link with the Pathology
by: Carmela Conte, et al.
Published: (2023-05-01)

Updates on Parkinson&rsquo;s Disease
by: Bai H, et al.
Published: (2025-09-01)